Patents by Inventor Mariana Gonzalez-Murguiondo

Mariana Gonzalez-Murguiondo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION
    Publication number: 20160220536
    Abstract: Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling.
    Type: Application
    Filed: February 19, 2016
    Publication date: August 4, 2016
    Inventors: Leonard D. Kohn, Norikazu Harii, Uruguaysito Benavides-Peralta, Mariana Gonzalez-Murguiondo, Christopher J. Lewis, Douglas J. Goetz, Giorgio Napolitano, Cesidio Giuliani, Ramiro Malgor, Frank Schwartz, Kelly D. McCall
  • Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
    Patent number: 9326972
    Abstract: Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 3, 2016
    Assignee: Ohio University
    Inventors: Leonard D. Kohn, Norikazu Harii, Uruguaysito Benavides-Peralta, Mariana Gonzalez-Murguiondo, Christopher J. Lewis, Douglas J. Goetz, Giorgio Napolitano, Cesidio Giuliani, Ramiro Malgor, Frank Schwartz, Kelly D. McCall
  • Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
    Publication number: 20120238610
    Abstract: Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling.
    Type: Application
    Filed: February 9, 2012
    Publication date: September 20, 2012
    Inventors: Leonard D. Kohn, Norikazu Harii, Uruguaysito Benavides-Peratta, Mariana Gonzalez-Murguiondo, Christopher J. Lewis, Douglas J. Goetz
  • Methods for the amelioration of episodes of acute or chronic ulcerative colitis
    Patent number: 7928132
    Abstract: Methods of ameliorating episodes of accute or chronic colitis are provided by using methimazole derivatives and tautomeric cyclic thiones in combination with another pharmaceutical compound.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: April 19, 2011
    Assignee: Ohio University
    Inventors: Leonard D. Kohn, Douglas J. Goetz, Uruguaysito Benavides-Peralta, Mariana Gonzalez-Murguiondo, Norikazu Harii, Christopher J. Lewis, Giorgio Napolitano, Nilesh D. Dagia
  • Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
    Publication number: 20060211752
    Abstract: The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies.
    Type: Application
    Filed: May 17, 2005
    Publication date: September 21, 2006
    Inventors: Leonard Kohn, Norikazu Harii, Uruguaysito Benavides-Peralta, Mariana Gonzalez-Murguiondo, Christopher Lewis, Giorgio Napolitano, Cesidio Giuliani, Ramiro Malgor, Douglas Goetz
  • Compositions and methods for treatment of colitis
    Publication number: 20060058365
    Abstract: The present invention relates to the treatment of inflammatory bowel disease (IBD) and related gastrointestinal pathologies. This invention also relates to the treatment of cytokine-mediated diseases, including tumor necrosis factor-? (TNF?)-induced diseases and/or chemokine-mediated diseases. This invention also relates to treating an animal having a disease or condition associated with Toll-like receptor 4. Specifically, the present invention relates to the treatment of inflammatory bowel disease (IBD) and related gastrointestinal pathologies that are cytokine-mediated or associated with Toll-like receptor 4. More specifically, this invention is directed to methods for treating or preventing IBD and related gastrointestinal pathologies using methimazole derivatives and tautomeric cyclic thiones.
    Type: Application
    Filed: August 6, 2004
    Publication date: March 16, 2006
    Inventors: Leonard Kohn, Douglas Goetz, Uruguaysito Benavides-Peralta, Mariana Gonzalez-Murguiondo, Norikazu Harii, Christopher Lewis, Giorgio Napolitano, Nilesh Dagia